NEW YORK ( TheStreet) -- "I really didn't want to see the markets up big today," Jim Cramer admitted to his "Mad Money" TV show viewers Thursday. Cramer said today's big market rally was every bit as phony as Wednesday's decline, and he still recommends selling into strength and repositioning into dividend-yielding stocks. Cramer explained that the problem with today's rally was that there wasn't anything fundamentally different to justify it. He said there was come good news, like Cisco's ( CSCO) great earnings after a year of bad ones, and the news of a European ban on short-selling coming soon. There was also pretty good jobless data here in the U.S. coupled with record levels of insider buying at U.S. companies. Finally there was gold, which finally started to retreat after margin requirements were strengthened. But does that warrant a 400-point rally? Cramer said we still have no leadership, either here or in Europe, and all of our leaders are still on vacation. The machines are still clearly in charge of the markets, he said, as noted by another day of big volatility. And the French banks are still in trouble, even if they won't admit it. Cramer made it clear that without fundamental changes the market will continue this trend of increased volatility going forward. He said the trend is a sign of sickness, not of health. The predictions of a bottom today are every bit as wrong as the predictions of Armageddon yesterday, he said. Cramer continued to urge investors to use any strength to reposition out of technology and the banks and into safer dividend stocks along with raising cash. "This market is not one you want to bet your nest egg or your childrens' college fund on," Cramer said.
High-Dividend Play"It's time to circle the wagons around high-yielding dividend stocks," Cramer told viewers. And in the big pharma arena, that means Sanofi-Aventis ( SNY) with its juicy 5% dividend yield. Shares of Sanofi were down 7.4% in Wednesday's big sell-off simply because the company is headquartered in France, the latest country to loath. Yet Sanofi only derives 10% of its revenues from its home country, making it now the cheapest of the big pharma stocks, trading at an astounding 6.8 times earnings, he said. Cramer said that Sanofi does face patent expiration problems like most of its peers, but at this point all of those worries are known and baked into the estimates. What's not being considered is the company's exposure to the fast-growing emerging markets, which accounts for 30% of sales and represents higher margins, he said. Sanofi has a panoply of drugs, everything from diabetes to cancer, and thanks to its acquisition of Genzyme, a portfolio of high-value orphan drugs used to treat rare diseases. The company is also a leader in vaccines, one market where there is high demand and no generic competition. In the cancer space, Sanofi has no blockbuster drugs in the pipeline, said Cramer, but it does have some small- and medium-sized projects showing encouraging results, he said. Given the company's valuation and its dividend, Cramer said Sanofi is a steal when compared to its peers. The company also has an analysts day coming up on Sept. 6, which should help the stock recover from its recent doldrums, he said.
Most Undervalued StockInvestors looking for a great long-term opportunity need to look at EOG Resources ( EOG - Get Report), which Cramer called the most unvalued stock in the entire stock market. Shares of EOG are down some 30 points from its 52-week high and is now trading at fire sale prices, said Cramer. EOG is a top oil producer in the Bakken shale region of our country and also has assets in Eagleford, Marcellus and many other shale plays to boot. But the compelling story of EOG is in how little the market values the company's assets. According to recent estimates, EOG's 561,000 highly productive acres of land in the Eagleford shale should be valued at $35,000 an acre, or $19.6 billion. That figure rivals EOG's total market cap of just $24 billion, despite Eagleford only representing 8% of the company's total production. Cramer explained that at these prices, investors are getting the rest of EOG essentially for free. The company also just delivered a 32-cent-a-share earnings beat on production that increased 89% year over year. Cramer said EOG's decision to move from natural gas to oil production was clearly the right move to make and the company is now benefitting handsomely. Cramer said he'd use the market weakness to scale into EOG right here and would buy more if the stock goes any lower.